 | • レポートコード：MRC23Q36062 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、86ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のヘパリン誘発性血小板減少症治療市場について調査・分析し、世界のヘパリン誘発性血小板減少症治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（活性化因子 X 阻害剤 ヘパリン誘発性血小板減少症治療、直接トロンビン阻害剤 ヘパリン誘発性血小板減少症治療、ヘパリノイド ヘパリン誘発性血小板減少症治療、フォンダパリヌクス ヘパリン誘発性血小板減少症治療、ヘパリン＆ビタミン K アンタゴニスト療法 ヘパリン誘発性血小板減少症治療）、用途別セグメント分析（病院、外来手術センター、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bayer Healthcare Pharmaceuticals Inc.、Pfizer Inc.、Janssen Pharmaceuticals, Inc.、Bristol-Myers Squibb Company、Eisai Co., Ltd、LEO Pharma A/S、Mylan N.V.、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Fresenius Kabi AG、Syntex S.A.、Celgene Corporation、Diapharma.などが含まれています。世界のヘパリン誘発性血小板減少症治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ヘパリン誘発性血小板減少症治療市場規模を推定する際に考慮しました。本レポートは、ヘパリン誘発性血小板減少症治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ヘパリン誘発性血小板減少症治療に関するビジネス上の意思決定に役立てることを目的としています。 ・ヘパリン誘発性血小板減少症治療市場の概要 - ヘパリン誘発性血小板減少症治療のタイプ別セグメント - 世界のヘパリン誘発性血小板減少症治療市場規模：タイプ別分析（活性化因子 X 阻害剤 ヘパリン誘発性血小板減少症治療、直接トロンビン阻害剤 ヘパリン誘発性血小板減少症治療、ヘパリノイド ヘパリン誘発性血小板減少症治療、フォンダパリヌクス ヘパリン誘発性血小板減少症治療、ヘパリン＆ビタミン K アンタゴニスト療法 ヘパリン誘発性血小板減少症治療） - ヘパリン誘発性血小板減少症治療の用途別セグメント - 世界のヘパリン誘発性血小板減少症治療市場規模：用途別分析（病院、外来手術センター、その他） - 世界のヘパリン誘発性血小板減少症治療市場規模予測（2018年-2029年） ・ヘパリン誘発性血小板減少症治療市場の成長トレンド - ヘパリン誘発性血小板減少症治療の地域別市場規模（2018年-2029年） - ヘパリン誘発性血小板減少症治療市場ダイナミクス - ヘパリン誘発性血小板減少症治療の業界動向 - ヘパリン誘発性血小板減少症治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：活性化因子 X 阻害剤 ヘパリン誘発性血小板減少症治療、直接トロンビン阻害剤 ヘパリン誘発性血小板減少症治療、ヘパリノイド ヘパリン誘発性血小板減少症治療、フォンダパリヌクス ヘパリン誘発性血小板減少症治療、ヘパリン＆ビタミン K アンタゴニスト療法 ヘパリン誘発性血小板減少症治療 - 世界のヘパリン誘発性血小板減少症治療のタイプ別市場規模（2018年-2023年） - 世界のヘパリン誘発性血小板減少症治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、外来手術センター、その他 - 世界のヘパリン誘発性血小板減少症治療の用途別市場規模（2018年-2023年） - 世界のヘパリン誘発性血小板減少症治療の用途別市場規模（2024年-2029年） ・ヘパリン誘発性血小板減少症治療の地域別市場規模 - 北米のヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - アメリカのヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - ヨーロッパのヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - アジア太平洋のヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - 中国のヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - 日本のヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - 韓国のヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - インドのヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - オーストラリアのヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - 中南米のヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） - 中東・アフリカのヘパリン誘発性血小板減少症治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bayer Healthcare Pharmaceuticals Inc.、Pfizer Inc.、Janssen Pharmaceuticals, Inc.、Bristol-Myers Squibb Company、Eisai Co., Ltd、LEO Pharma A/S、Mylan N.V.、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Fresenius Kabi AG、Syntex S.A.、Celgene Corporation、Diapharma. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Heparin-induced Thrombocytopenia Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Heparin-induced Thrombocytopenia Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Heparin-induced Thrombocytopenia Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Heparin-induced Thrombocytopenia Treatment in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Heparin-induced Thrombocytopenia Treatment include Bayer Healthcare Pharmaceuticals Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Co., Ltd, LEO Pharma A/S, Mylan N.V., Sanofi S.A. and Teva Pharmaceutical Industries Ltd., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Heparin-induced Thrombocytopenia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heparin-induced Thrombocytopenia Treatment.
The Heparin-induced Thrombocytopenia Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Heparin-induced Thrombocytopenia Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Heparin-induced Thrombocytopenia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bayer Healthcare Pharmaceuticals Inc.
Pfizer Inc.
Janssen Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Eisai Co., Ltd
LEO Pharma A/S
Mylan N.V.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Fresenius Kabi AG
Syntex S.A.
Celgene Corporation
Diapharma.
Segment by Type
Activated Factor X Inhibitors Heparin-Induced Thrombocytopenia Treatment
Direct Thrombin Inhibitors Heparin-Induced Thrombocytopenia Treatment
Heparinoids Heparin-Induced Thrombocytopenia Treatment
Fondaparinux Heparin-Induced Thrombocytopenia Treatment
Heparin And Vitamin K Antagonist Therapy Heparin-Induced Thrombocytopenia Treatment
Segment by Application
Hospitals
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Heparin-induced Thrombocytopenia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Heparin-induced Thrombocytopenia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Activated Factor X Inhibitors Heparin-Induced Thrombocytopenia Treatment
1.2.3 Direct Thrombin Inhibitors Heparin-Induced Thrombocytopenia Treatment
1.2.4 Heparinoids Heparin-Induced Thrombocytopenia Treatment
1.2.5 Fondaparinux Heparin-Induced Thrombocytopenia Treatment
1.2.6 Heparin And Vitamin K Antagonist Therapy Heparin-Induced Thrombocytopenia Treatment
1.3 Market by Application
1.3.1 Global Heparin-induced Thrombocytopenia Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Heparin-induced Thrombocytopenia Treatment Market Perspective (2018-2029)
2.2 Heparin-induced Thrombocytopenia Treatment Growth Trends by Region
2.2.1 Global Heparin-induced Thrombocytopenia Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Heparin-induced Thrombocytopenia Treatment Historic Market Size by Region (2018-2023)
2.2.3 Heparin-induced Thrombocytopenia Treatment Forecasted Market Size by Region (2024-2029)
2.3 Heparin-induced Thrombocytopenia Treatment Market Dynamics
2.3.1 Heparin-induced Thrombocytopenia Treatment Industry Trends
2.3.2 Heparin-induced Thrombocytopenia Treatment Market Drivers
2.3.3 Heparin-induced Thrombocytopenia Treatment Market Challenges
2.3.4 Heparin-induced Thrombocytopenia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Heparin-induced Thrombocytopenia Treatment Players by Revenue
3.1.1 Global Top Heparin-induced Thrombocytopenia Treatment Players by Revenue (2018-2023)
3.1.2 Global Heparin-induced Thrombocytopenia Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Heparin-induced Thrombocytopenia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Heparin-induced Thrombocytopenia Treatment Revenue
3.4 Global Heparin-induced Thrombocytopenia Treatment Market Concentration Ratio
3.4.1 Global Heparin-induced Thrombocytopenia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Heparin-induced Thrombocytopenia Treatment Revenue in 2022
3.5 Heparin-induced Thrombocytopenia Treatment Key Players Head office and Area Served
3.6 Key Players Heparin-induced Thrombocytopenia Treatment Product Solution and Service
3.7 Date of Enter into Heparin-induced Thrombocytopenia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Heparin-induced Thrombocytopenia Treatment Breakdown Data by Type
4.1 Global Heparin-induced Thrombocytopenia Treatment Historic Market Size by Type (2018-2023)
4.2 Global Heparin-induced Thrombocytopenia Treatment Forecasted Market Size by Type (2024-2029)
5 Heparin-induced Thrombocytopenia Treatment Breakdown Data by Application
5.1 Global Heparin-induced Thrombocytopenia Treatment Historic Market Size by Application (2018-2023)
5.2 Global Heparin-induced Thrombocytopenia Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
6.2 North America Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
6.4 North America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
7.2 Europe Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
7.4 Europe Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
8.2 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Heparin-induced Thrombocytopenia Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
9.2 Latin America Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
9.4 Latin America Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Size (2018-2029)
10.2 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Heparin-induced Thrombocytopenia Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer Healthcare Pharmaceuticals Inc.
11.1.1 Bayer Healthcare Pharmaceuticals Inc. Company Detail
11.1.2 Bayer Healthcare Pharmaceuticals Inc. Business Overview
11.1.3 Bayer Healthcare Pharmaceuticals Inc. Heparin-induced Thrombocytopenia Treatment Introduction
11.1.4 Bayer Healthcare Pharmaceuticals Inc. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.1.5 Bayer Healthcare Pharmaceuticals Inc. Recent Development
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Detail
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Heparin-induced Thrombocytopenia Treatment Introduction
11.2.4 Pfizer Inc. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.2.5 Pfizer Inc. Recent Development
11.3 Janssen Pharmaceuticals, Inc.
11.3.1 Janssen Pharmaceuticals, Inc. Company Detail
11.3.2 Janssen Pharmaceuticals, Inc. Business Overview
11.3.3 Janssen Pharmaceuticals, Inc. Heparin-induced Thrombocytopenia Treatment Introduction
11.3.4 Janssen Pharmaceuticals, Inc. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.3.5 Janssen Pharmaceuticals, Inc. Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Detail
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Heparin-induced Thrombocytopenia Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Eisai Co., Ltd
11.5.1 Eisai Co., Ltd Company Detail
11.5.2 Eisai Co., Ltd Business Overview
11.5.3 Eisai Co., Ltd Heparin-induced Thrombocytopenia Treatment Introduction
11.5.4 Eisai Co., Ltd Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.5.5 Eisai Co., Ltd Recent Development
11.6 LEO Pharma A/S
11.6.1 LEO Pharma A/S Company Detail
11.6.2 LEO Pharma A/S Business Overview
11.6.3 LEO Pharma A/S Heparin-induced Thrombocytopenia Treatment Introduction
11.6.4 LEO Pharma A/S Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.6.5 LEO Pharma A/S Recent Development
11.7 Mylan N.V.
11.7.1 Mylan N.V. Company Detail
11.7.2 Mylan N.V. Business Overview
11.7.3 Mylan N.V. Heparin-induced Thrombocytopenia Treatment Introduction
11.7.4 Mylan N.V. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.7.5 Mylan N.V. Recent Development
11.8 Sanofi S.A.
11.8.1 Sanofi S.A. Company Detail
11.8.2 Sanofi S.A. Business Overview
11.8.3 Sanofi S.A. Heparin-induced Thrombocytopenia Treatment Introduction
11.8.4 Sanofi S.A. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.8.5 Sanofi S.A. Recent Development
11.9 Teva Pharmaceutical Industries Ltd.
11.9.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.9.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.9.3 Teva Pharmaceutical Industries Ltd. Heparin-induced Thrombocytopenia Treatment Introduction
11.9.4 Teva Pharmaceutical Industries Ltd. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.9.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.10 Fresenius Kabi AG
11.10.1 Fresenius Kabi AG Company Detail
11.10.2 Fresenius Kabi AG Business Overview
11.10.3 Fresenius Kabi AG Heparin-induced Thrombocytopenia Treatment Introduction
11.10.4 Fresenius Kabi AG Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.10.5 Fresenius Kabi AG Recent Development
11.11 Syntex S.A.
11.11.1 Syntex S.A. Company Detail
11.11.2 Syntex S.A. Business Overview
11.11.3 Syntex S.A. Heparin-induced Thrombocytopenia Treatment Introduction
11.11.4 Syntex S.A. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.11.5 Syntex S.A. Recent Development
11.12 Celgene Corporation
11.12.1 Celgene Corporation Company Detail
11.12.2 Celgene Corporation Business Overview
11.12.3 Celgene Corporation Heparin-induced Thrombocytopenia Treatment Introduction
11.12.4 Celgene Corporation Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.12.5 Celgene Corporation Recent Development
11.13 Diapharma.
11.13.1 Diapharma. Company Detail
11.13.2 Diapharma. Business Overview
11.13.3 Diapharma. Heparin-induced Thrombocytopenia Treatment Introduction
11.13.4 Diapharma. Revenue in Heparin-induced Thrombocytopenia Treatment Business (2018-2023)
11.13.5 Diapharma. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details